Valeant Pharmaceuticals International Inc. reached a deal to sell its iNova Pharmaceuticals unit for $930 million, as it works to reset itself after a crisis, cutting billions in debt and refocusing on its core treatment areas and geographies.
from WSJ.com: US Business http://ift.tt/2qZPtHg
via IFTTT
No comments:
Post a Comment